Premium
Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults
Author(s) -
Roohullah A.,
Moniwa A.,
Wood C.,
Humble M.,
Balm M.,
Carter J.,
Weinkove R.
Publication year - 2013
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12226
Subject(s) - medicine , piperacillin/tazobactam , cefepime , imipenem , piperacillin , tazobactam , neutropenia , clostridium difficile , empiric therapy , antibiotics , cohort , febrile neutropenia , intensive care medicine , chemotherapy , microbiology and biotechnology , antibiotic resistance , genetics , alternative medicine , pathology , bacteria , pseudomonas aeruginosa , biology
Australian guidelines for neutropenic fever recommend piperacillin/tazobactam ( PIP‐TAZ ) or cefepime for first‐line empiric treatment of neutropenic fever. We compared outcomes among haematology patients before and after changing our first‐line neutropenic fever treatment from imipenem to PIP‐TAZ . Forty‐five patients received imipenem and 60 PIP‐TAZ . Despite a higher rate of antibiotic modification in the PIP‐TAZ cohort, treatment success and time to defervescence were similar, with a trend towards fewer C lostridium difficile infections in the PIP‐TAZ cohort.